GeoVax Labs updates investors on its COVID-19 vaccine and cancer immunotherapy clinical trials
GeoVax Labs CEO David Dodd talks to Proactive about its three separate ongoing Phase II clinical trials in developing a COVID-19 booster to mRNA vaccines, a COVID-19 vaccine to immunocompromised patients, and and a cancer immunotherapy for advanced head and neck cancer. Dodd says each are progressing well, and he says, the company is currently funded until the second quarter of 2023.View Price & Profile